These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38362654)

  • 41. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Knowledge, attitudes and perspective on adverse drug reaction reporting in a public sector hospital in South Africa: baseline analysis.
    Terblanche A; Meyer JC; Godman B; Summers RS
    Hosp Pract (1995); 2017 Dec; 45(5):238-245. PubMed ID: 28914115
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regulatory requirements for the registration of generic medicines and format of drug dossiers: procedures in Sri Lanka in comparison with selected regulatory authorities.
    Thambavita D; Galappatthy P; Jayakody RL
    J Pharm Policy Pract; 2018; 11():14. PubMed ID: 29951208
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Specific features of medicines safety and pharmacovigilance in Africa.
    Isah AO; Pal SN; Olsson S; Dodoo A; Bencheikh RS
    Ther Adv Drug Saf; 2012 Feb; 3(1):25-34. PubMed ID: 25083223
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Using resources for scientific-driven pharmacovigilance: from many product safety documents to one product safety master file.
    Furlan G
    Drug Saf; 2012 Aug; 35(8):615-22. PubMed ID: 22788233
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Importation and distribution of unregistered medicines in the public sector: similarities, differences, and shared challenges among Southern African Development Community (SADC) countries.
    Nyika A; Ngara B; Mutingwende I; Gwaza L
    BMC Health Serv Res; 2022 Apr; 22(1):570. PubMed ID: 35484525
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Direct healthcare professional communications: A quantitative assessment study.
    Alsaleh H; Alshammari TM
    Pharmacol Res Perspect; 2021 May; 9(3):e00763. PubMed ID: 33929085
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacovigilance of biopharmaceuticals: challenges remain.
    Giezen TJ; Mantel-Teeuwisse AK; Leufkens HG
    Drug Saf; 2009; 32(10):811-7. PubMed ID: 19722725
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Knowledge, attitudes and practice regarding pharmacovigilance and adverse drug reaction reporting among physicians and pharmacists in Egypt: a step toward personalized medicine implementation.
    Aziz AA; Rogers S; Hassanien O; Shalaby L; Nagy M
    Per Med; 2022 Nov; 19(6):495-507. PubMed ID: 36239598
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Authoring a periodic adverse drug experience report…here's what you need to know!
    Kulkarni TN; Kulkarni NG
    Perspect Clin Res; 2019; 10(2):95-99. PubMed ID: 31008077
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical practice guidelines within the Southern African Development Community: a descriptive study of the quality of guideline development and concordance with best evidence for five priority diseases.
    Kredo T; Gerritsen A; van Heerden J; Conway S; Siegfried N
    Health Res Policy Syst; 2012 Jan; 10():1. PubMed ID: 22221856
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improving epidemic malaria planning, preparedness and response in Southern Africa. Report on the 1st Southern African Regional Epidemic Outlook Forum, Harare, Zimbabwe, 26-29 September, 2004.
    DaSilva J; Garanganga B; Teveredzi V; Marx SM; Mason SJ; Connor SJ
    Malar J; 2004 Oct; 3():37. PubMed ID: 15500683
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparative analysis of the pharmacovigilance systems of Brazil, Spain, the European Union and the United States based on the information provided by their regulatory agency websites.
    Leal MM; Sanz MM; Ferrando JRC; Martinez-Martinez F
    Daru; 2019 Jun; 27(1):379-387. PubMed ID: 30778915
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A desktop review of evaluation of implementation of national medicines policies in SADC countries.
    Modiba WK; Katerere DR; Mncwangi NP
    Heliyon; 2023 Nov; 9(11):e22218. PubMed ID: 38045165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.
    Durrieu G; Palmaro A; Pourcel L; Caillet C; Faucher A; Jacquet A; Ouaret S; Perault-Pochat MC; Kreft-Jais C; Castot A; Lapeyre-Mestre M; Montastruc JL;
    Drug Saf; 2012 Oct; 35(10):845-54. PubMed ID: 22967189
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety reporting through a comprehensive and pragmatic pharmcovigilance process for India and emerging markets: an industry perspective.
    Swamy S; Mourya M; Kadhe G; Mane A; Sawant S
    Expert Opin Drug Saf; 2015; 14(9):1409-20. PubMed ID: 26292785
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aggregate analysis of regulatory authority assessors' comments to improve the quality of periodic safety update reports.
    Jullian S; Jaskiewicz L; Pfannkuche HJ; Parker J; Lalande-Luesink I; Lewis DJ; Close P
    Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):971-9. PubMed ID: 26175055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.